Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Treasury Shares: 2012-2025

Historic Treasury Shares for Agios Pharmaceuticals (AGIO) over the last 5 years, with Sep 2025 value amounting to $802.5 million.

  • Agios Pharmaceuticals' Treasury Shares changed negligibly% to $802.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $802.5 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $802.5 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Treasury Shares stood at $16.2 million, which was down 0.00% from $16.2 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Treasury Shares registered a high of $16.2 billion during Q1 2022, and its lowest value of $7.1 million during Q1 2021.
  • In the last 3 years, Agios Pharmaceuticals' Treasury Shares had a median value of $16.2 billion in 2024 and averaged $10.3 billion.
  • Data for Agios Pharmaceuticals' Treasury Shares shows a peak YoY spiked of 51.69% (in 2022) over the last 5 years.
  • Over the past 5 years, Agios Pharmaceuticals' Treasury Shares (Quarterly) stood at $802.5 million in 2021, then remained steady at $802.5 million in 2022, then remained steady at $802.5 million in 2023, then remained steady at $802.5 million in 2024, then remained steady at $802.5 million in 2025.
  • Its Treasury Shares was $802.5 million in Q3 2025, compared to $802.5 million in Q2 2025 and $802.5 million in Q1 2025.